New Hope, Funding Approaches As Roche Brings Evrysdi To India

Zolgensma Provided In India Through Managed Access Program

Roche’s Evrysdi debuts in India backed by a patient support program ahead of Novartis’ Zolgensma and Biogen’s Spinraza. Spotlights remains on the price tag for the SMA therapy amid hopes that novel approaches such as crowdfunding could also broaden access.

Roche bldg
Evrysdi Is Now Available In India • Source: Alamy

Roche has brought Evrysdi (risdiplam) to India ahead of rival spinal muscular atrophy (SMA) treatments Novartis AG’ Zolgensma (onasemnogene abeparvovec) and Biogen, Inc.’s Spinraza (nusinersen), backed by a patient support program (PSP) that could potentially soften the pricing blow for patients in a largely out-of-pocket market.

Evrysdi, the first and only oral SMA treatment, comes at a maximum retail price of around INR600,000 ($8,067) per bottle...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip